Beijing Tong Ren Tang Chinese Medicine (SEHK:3613) - Prezzo delle azioni, notizie e analisi

3613 Panoramica delle azioni

3613 analisi fondamentale
Punteggio fiocco di neve
Valutazione	1/6
Crescita futura	3/6
Prestazioni passate	1/6
Salute finanziaria	5/6
Dividendi	4/6

Premi

Negoziato a 19.8% al di sotto della nostra stima del suo valore equo

Si prevede che gli utili cresceranno del 16.51% all'anno

Analisi del rischio

Elevato livello di guadagni non monetari

Il dividendo di 4.09% non è ben coperto dai flussi di cassa liberi

Beijing Tong Ren Tang Chinese Medicine Company Limited Concorrenti

Tong Ren Tang Technologies

SEHK:1666

HK$6.7b

Consun Pharmaceutical Group

SEHK:1681

HK$7.0b

China Shineway Pharmaceutical Group

SEHK:2877

HK$6.3b

Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd

SEHK:1349

HK$7.3b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Beijing Tong Ren Tang Chinese Medicine
Prezzi storici delle azioni
Prezzo attuale dell'azione	HK$8.06
Massimo di 52 settimane	HK$13.44
Minimo di 52 settimane	HK$7.03
Beta	0.47
1Variazione di 1 mese	-3.70%
Variazione a 3 mesi	-7.89%
Variazione di 1 anno	-35.00%
3Variazione a 3 anni	-19.32%
Variazione a 5 anni	-20.20%
Variazione dall'IPO	23.43%

Notizie e aggiornamenti recenti

Beijing Tong Ren Tang Chinese Medicine Company Limited's (HKG:3613) Shares Climb 32% But Its Business Is Yet to Catch Up

Oct 04

Earnings Troubles May Signal Larger Issues for Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Shareholders

Sep 06

Recent updates

Beijing Tong Ren Tang Chinese Medicine Company Limited's (HKG:3613) Shares Climb 32% But Its Business Is Yet to Catch Up

Oct 04

Earnings Troubles May Signal Larger Issues for Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Shareholders

Sep 06

Is There An Opportunity With Beijing Tong Ren Tang Chinese Medicine Company Limited's (HKG:3613) 31% Undervaluation?

Sep 02

Beijing Tong Ren Tang Chinese Medicine Company Limited's (HKG:3613) 28% Share Price Plunge Could Signal Some Risk

Feb 05

Calculating The Intrinsic Value Of Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613)

Jan 03

A Look At The Intrinsic Value Of Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613)

Sep 28

Here's Why We Think Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Might Deserve Your Attention Today

Jul 12

Is Now The Time To Put Beijing Tong Ren Tang Chinese Medicine (HKG:3613) On Your Watchlist?

Mar 29

Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Has Announced That It Will Be Increasing Its Dividend To HK$0.28

Apr 28

Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Will Pay A Larger Dividend Than Last Year At HK$0.28

Mar 25

Are Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Investors Paying Above The Intrinsic Value?

Oct 27

Beijing Tong Ren Tang Chinese Medicine's (HKG:3613) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Apr 28

Read This Before Selling Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Shares

Mar 11

What Type Of Returns Would Beijing Tong Ren Tang Chinese Medicine's(HKG:3613) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Feb 04

Should Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Be Part Of Your Dividend Portfolio?

Jan 18

Could The Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Ownership Structure Tell Us Something Useful?

Dec 29

Read This Before Selling Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Shares

Dec 11

Beijing Tong Ren Tang Chinese Medicine Company Limited's (HKG:3613) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Nov 23

Rendimenti per gli azionisti

	3613	HK Pharmaceuticals	HK Mercato
7D	-2.7%	-2.0%	-2.7%
1Y	-35.0%	-9.4%	10.9%

Ritorno vs Industria: 3613 ha avuto una performance inferiore rispetto al Hong Kong Pharmaceuticals che ha registrato un rendimento -9.4 % nell'ultimo anno.

Rendimento vs Mercato: 3613 ha avuto una performance inferiore al mercato Hong Kong che ha registrato un rendimento 10.9 % nell'ultimo anno.

Volatilità dei prezzi

Is 3613's price volatile compared to industry and market?
3613 volatility
3613 Average Weekly Movement	6.7%
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	9.0%
10% most volatile stocks in HK Market	19.0%
10% least volatile stocks in HK Market	4.2%

Prezzo delle azioni stabile: 3613 non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 7% ) di 3613 è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
1669	779	Wang Chi	www.tongrentangcm.com

Beijing Tong Ren Tang Chinese Medicine Company Limited, insieme alle sue controllate, si occupa della produzione, della vendita al dettaglio e della vendita all'ingrosso di prodotti sanitari e di medicina cinese a grossisti e privati. La società opera attraverso tre segmenti: Hong Kong, Cina continentale e oltremare. Offre anche servizi di consulenza e trattamento medico cinese.

Beijing Tong Ren Tang Chinese Medicine Company Limited Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Beijing Tong Ren Tang Chinese Medicine con la sua capitalizzazione di mercato?
3613 statistiche fondamentali
Capitalizzazione di mercato	HK$6.75b
Guadagni(TTM)	HK$494.14m
Ricavi(TTM)	HK$1.38b

13.7x

Rapporto P/E

4.9x

Rapporto P/S

3613 è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
3613 Conto economico (TTM)
Ricavi	HK$1.38b
Costo del fatturato	HK$384.69m
Profitto lordo	HK$991.96m
Altre spese	HK$497.83m
Guadagni	HK$494.14m

Ultimi guadagni dichiarati

Jun 30, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	0.59
Margine lordo	72.06%
Margine di profitto netto	35.89%
Rapporto debito/patrimonio netto	0.006%

Come si è comportato 3613 nel lungo periodo?

Vedi performance storica e confronto

Dividendi

4.1%

Rendimento attuale del dividendo

56%

Rapporto di remunerazione

3613 Panoramica delle azioni

Premi

Analisi del rischio

Beijing Tong Ren Tang Chinese Medicine Company Limited Concorrenti

SEHK:1666

HK$6.7b

SEHK:1681

HK$7.0b

SEHK:2877

HK$6.3b

SEHK:1349

HK$7.3b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Now 20% undervalued after recent price drop

Now 20% undervalued after recent price drop

Beijing Tong Ren Tang Chinese Medicine Company Limited's (HKG:3613) Shares Climb 32% But Its Business Is Yet to Catch Up

Investor sentiment improves as stock rises 22%

Earnings Troubles May Signal Larger Issues for Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Shareholders

First half 2024 earnings released: EPS: HK$0.26 (vs HK$0.32 in 1H 2023)

Recent updates

Now 20% undervalued after recent price drop

Now 20% undervalued after recent price drop

Beijing Tong Ren Tang Chinese Medicine Company Limited's (HKG:3613) Shares Climb 32% But Its Business Is Yet to Catch Up

Investor sentiment improves as stock rises 22%

Earnings Troubles May Signal Larger Issues for Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Shareholders

First half 2024 earnings released: EPS: HK$0.26 (vs HK$0.32 in 1H 2023)

Is There An Opportunity With Beijing Tong Ren Tang Chinese Medicine Company Limited's (HKG:3613) 31% Undervaluation?

New major risk - Earnings quality

Beijing Tong Ren Tang Chinese Medicine Company Limited to Report First Half, 2024 Results on Aug 30, 2024

Beijing Tong Ren Tang Chinese Medicine Company Limited Approves Final Dividend for the Year Ended December 31, 2023

Now 22% overvalued after recent price rise

Upcoming dividend of HK$0.33 per share

Less than half of directors are independent

Beijing Tong Ren Tang Chinese Medicine Company Limited Appoints Wang Chi as an Executive Director and a Member of the Competition Executive Committee

Now 21% overvalued after recent price rise

Full year 2023 earnings: EPS and revenues miss analyst expectations

Beijing Tong Ren Tang Chinese Medicine Company Limited Announces CEO Changes

Beijing Tong Ren Tang Chinese Medicine Company Limited, Annual General Meeting, May 31, 2024

New minor risk - Financial data availability

Beijing Tong Ren Tang Chinese Medicine Company Limited's (HKG:3613) 28% Share Price Plunge Could Signal Some Risk

Price target decreased by 14% to HK$14.93

Investor sentiment deteriorates as stock falls 16%

Beijing Tong Ren Tang Chinese Medicine Company Limited to Report Fiscal Year 2023 Results on Mar 31, 2024

Now 21% undervalued after recent price drop

Calculating The Intrinsic Value Of Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613)

Less than half of directors are independent

Beijing Tong Ren Tang Chinese Medicine Company Limited Appoints Gu Hai Ou as Executive Director, Chairman of Board and Authorised Representative

Beijing Tong Ren Tang Chinese Medicine Company Limited to Report Nine Months, 2023 Results on Oct 31, 2023

A Look At The Intrinsic Value Of Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613)

Beijing Tong Ren Tang Chinese Medicine Company Limited Announces Resignation of Lin Man as Executive Director, Chief Operating Officer, Member of Competition Executive Committee

Beijing Tong Ren Tang Chinese Medicine Company Limited Announces Retirement of Ding Yong Ling as Executive Director and Chairman of the Board

First half 2023 earnings released: EPS: HK$0.32 (vs HK$0.26 in 1H 2022)

Beijing Tong Ren Tang Chinese Medicine Company Limited to Report First Half, 2023 Results on Aug 10, 2023

Here's Why We Think Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Might Deserve Your Attention Today

Beijing Tong Ren Tang Chinese Medicine Company Limited Approves Final Dividend for the Year Ended 31 December 2022

Upcoming dividend of HK$0.33 per share at 2.1% yield

Is Now The Time To Put Beijing Tong Ren Tang Chinese Medicine (HKG:3613) On Your Watchlist?

Price target increased by 8.0% to HK$14.66

Less than half of directors are independent

Beijing Tong Ren Tang Chinese Medicine Company Limited to Report Nine Months, 2022 Results on Oct 31, 2022

Upcoming dividend of HK$0.25 per share

Beijing Tong Ren Tang Chinese Medicine Company Limited Proposes Special Interim Dividend, Payable on 21 October 2022

High number of new directors

COO & Executive Director recently bought HK$183k worth of stock

Price target decreased to HK$13.57

First half 2022 earnings released

Beijing Tong Ren Tang Chinese Medicine Company Limited Appoints Feng Li as Executive Director

Beijing Tong Ren Tang Chinese Medicine Company Limited to Report First Half, 2022 Results on Aug 12, 2022

Investor sentiment improved over the past week

Upcoming dividend of HK$0.28 per share

Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Has Announced That It Will Be Increasing Its Dividend To HK$0.28

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Beijing Tong Ren Tang Chinese Medicine Company Limited Proposes Final Dividend for the Year Ended 31 December 2021

Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Will Pay A Larger Dividend Than Last Year At HK$0.28

Investor sentiment improved over the past week

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Beijing Tong Ren Tang Chinese Medicine Company Limited to Report Fiscal Year 2021 Results on Mar 07, 2022

Investor sentiment improved over the past week

CEO & Executive Director recently bought HK$178k worth of stock